Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge? - Yahoo Finance
Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge? Yahoo Finance
Other news to note for Nov. 25, 2025
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Actimed, Aptose, Austrianova, Avant, Celltrion,...
Regulatory actions for Nov. 25, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Celltrion, Hen...
IgG4-related disease Market Size was USD 170 million in 2024, estimates DelveInsight | Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Takeda - Barchart.com
IgG4-related disease Market Size was USD 170 million in 2024, estimates DelveInsight | Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Ta...
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
Late-breaking abstracts from the annual American Society of Hematology meeting are early this year, coming right before Thanksgiving instead of the previously planned d...
Roche Adopts Veeva Vault CRM - Contract Pharma
Roche Adopts Veeva Vault CRM Contract Pharma
Data back spinal injury bid from Nervgen in phase Ib/IIa
Nervgen Pharma Corp. rolled out expanded findings from the Connect phase Ib/IIa study with NVG-291 in spinal cord injury patients showing that the 35-amino acid peptide...
Appointments and advancements for Nov. 24, 2025
BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Appointments and advancements for Nov. 24, 2025 Nov. 24, 2025 New hires and promotion...
Financings for Nov. 24, 2025
BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Financings for Nov. 24, 2025 Nov. 24, 2025 Biopharmas raising money in public or priv...
Other news to note for Nov. 24, 2025
Biopharma happenings, including deals and partnerships, and other news in brief: Actimed, Anaptysbio, GSK, Lava, Tesaro, Xoma.
Biggest gainers and losers for Nov. 17-21, 2025
BioWorld - Friday, December 26, 2025 To read the full article sign up for free or sign in. Biggest gainers and losers for Nov. 17-21, 2025 Nov. 24, 2025 The top 10 biop...
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
Recursion Pharmaceuticals Surpasses Third-Quarter Expectations, Announces Milestone with Roche - StocksToTrade
Recursion Pharmaceuticals Surpasses Third-Quarter Expectations, Announces Milestone with Roche StocksToTrade
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - MSN
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know MSN
Teva loses IRA drug pricing challenge in DC federal court
Teva’s challenge against Medicare negotiations fell flat in DC federal court, marking another loss for the pharma industry. US District Judge Sparkle Sooknanan said Thu...
Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna
Plus, news about Blue Lake, Bambusa, Inhibikase Therapeutics and Olema Oncology: 🛑 Sarepta terminates Elevidys trial with Hansa Biopharma’s imlifidase: The study was e...
Lilly becomes first $1 trillion pharma company
Eli Lilly's market valuation briefly reached more than a trillion dollars on Friday, making it the first-ever drugmaker to reach that benchmark. It hit the 13-digit val...